NCT00697931View on ClinicalTrials.gov

Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders

PHASE3CompletedINTERVENTIONAL

Enrollment

116

Participants

Timeline

Start Date

May 31, 1997

Primary Completion Date

June 30, 1998

Study Completion Date

June 30, 1998

Conditions

Hepatitis B

Interventions

BIOLOGICAL

Recombinant MPL- adjuvanted hepatitis B vaccine

Intramuscular injection, 3 doses

BIOLOGICAL

Engerix™-B

Intramuscular injection, 3 doses

Trial Locations (1)

Unknown

GSK Clinical Trials Call Center, Leuven

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00697931 - Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders | Biotech Hunter | Biotech Hunter